NEXTBio Capital Management LP
13F Reported Value
ⓘ$215.4M
Holdings
24
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
NEXTBio Capital Management LP disclosed 24 positions worth $215.4M in its Form 13F-HR for Q1 2026, led by $TERN (Terns Pharmaceuticals, Inc.) at 14.8% of the equity portfolio, followed by $PTGX and $STTK. During the quarter the fund opened 1 new position and exited 0 — including a new stake in $SMMT. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from NEXTBio Capital Management LP’s Form 13F-HR filing with the SEC under CIK 2038158.
Sector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$31.9M604,534 sh - 24.8#2,572
Quality
$24.2M229,619 sh - —
Quality
$20.3M3,149,907 sh - —
Quality
$17.8M999,967 sh - —
Quality
$11.2M2,021,407 sh - 30.3
Quality
$11.0M126,078 sh - 12.9
Quality
$10.7M183,225 sh - —
Quality
$10.3M82,686 sh - 14.4
Quality
$8.3M426,736 sh - —
Quality
$7.4M1,333,484 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Terns Pharmaceuticals, Inc.$TERN | — | $31.9M | 604,534 |
 Protagonist Therapeutics, Inc$PTGX | 24.8#2,572 | $24.2M | 229,619 |
 Shattuck Labs, Inc.$STTK | — | $20.3M | 3,149,907 |
 Vor Biopharma Inc.$VOR | — | $17.8M | 999,967 |
 COMPASS Pathways plc$CMPS | — | $11.2M | 2,021,407 |
 RHYTHM PHARMACEUTICALS, INC.$RYTM | 30.3 | $11.0M | 126,078 |
 Xenon Pharmaceuticals Inc.$XENE | 12.9 | $10.7M | 183,225 |
 PALVELLA THERAPEUTICS, INC.$PVLA | — | $10.3M | 82,686 |
 Zenas BioPharma, Inc.$ZBIO | 14.4 | $8.3M | 426,736 |
 Inventiva S.A.$IVA | — | $7.4M | 1,333,484 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of NEXTBio Capital Management LP's 24 positions.
Showing top 10 of 24 holdings.
Sector Allocation
Healthcare
$215.4M
Full Holdings — NEXTBio Capital Management LP (Q1 2026)
All 24 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $TERN | Terns Pharmaceuticals, Inc. | $31.9M | 14.8% | +10% | — |
| 2 | $PTGX | Protagonist Therapeutics, Inc | $24.2M | 11.2% | +0% | 24.8 |
| 3 | $STTK | Shattuck Labs, Inc. | $20.3M | 9.4% | +0% | — |
| 4 | $VOR | Vor Biopharma Inc. | $17.8M | 8.3% | +0% | — |
| 5 | $CMPS | COMPASS Pathways plc | $11.2M | 5.2% | +169% | — |
| 6 | $RYTM | RHYTHM PHARMACEUTICALS, INC. | $11.0M | 5.1% | +87% | 30.3 |
| 7 | $XENE | Xenon Pharmaceuticals Inc. | $10.7M | 5.0% | -0% | 12.9 |
| 8 | $PVLA | PALVELLA THERAPEUTICS, INC. | $10.3M | 4.8% | +0% | — |
| 9 | $ZBIO | Zenas BioPharma, Inc. | $8.3M | 3.9% | +33% | 14.4 |
| 10 | $IVA | Inventiva S.A. | $7.4M | 3.4% | +3% | — |
| 11 |  $VSTM | Verastem, Inc. | $6.9M | 3.2% | -0% | 40.8 |
| 12 |  $CBIO | CRESCENT BIOPHARMA, INC. | $6.8M | 3.2% | +0% | 28 |
| 13 |  $ORIC | Oric Pharmaceuticals, Inc. | $6.6M | 3.1% | -15% | — |
| 14 |  $GPCR | Structure Therapeutics Inc. | $6.4M | 3.0% | +41% | — |
| 15 |  $PCVX | Vaxcyte, Inc. | $5.5M | 2.6% | -0% | — |
| 16 |  $COGT | Cogent Biosciences, Inc. | $5.0M | 2.3% | +37% | — |
| 17 |  $CMPX | Compass Therapeutics, Inc. | $4.5M | 2.1% | -24% | — |
| 18 |  $EVMN | Evommune, Inc. | $4.2M | 2.0% | -19% | — |
| 19 |  $OCS | Oculis Holding AG | $4.0M | 1.9% | -0% | — |
| 20 |  $ZLAB | Zai Lab Ltd | $3.4M | 1.6% | +12% | — |
| 21 |  $IRON | Disc Medicine, Inc. | $3.4M | 1.6% | +23% | — |
| 22 |  $KALV | KalVista Pharmaceuticals, Inc. | $2.7M | 1.2% | +0% | 25.9 |
| 23 |  $SMMT | Summit Therapeutics Inc. | $1.7M | 0.8% | NEW | — |
| 24 |  $ACET | Adicet Bio, Inc. | $1.1M | 0.5% | +0% | — |
New Positions (1)
$SMMT Summit Therapeutics Inc.$1.7MBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for NEXTBio Capital Management LP including:
Track NEXTBio Capital Management LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for NEXTBio Capital Management LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: NEXTBio Capital Management LP
13F Pro is an AI hedge fund tracker and stock research platform. For NEXTBio Capital Management LP (SEC CIK: 2038158), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in NEXTBio Capital Management LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.